glp 1 cardiovascular benefit The Many Benefits of GLP-1 Drugs The conversation around GLP-1 medications

Liraglutide (LEADER trial), semaglutide (SUSTAIN-6), and dulaglutide (REWIND trial) have shown significant reductions in major adverse cardiovascular events (MACE) in patients with established cardiovascular disease or multiple cardiovascular risk factors

Besides, Baggio and Drucker [99] and Allegretti et al

For weight management in the UK, NICE-approved options are limited to orlistat (available over-the-counter or on prescription) and, within specialist weight management services, liraglutide 3.0mg (Saxenda) or semaglutide 2.4mg (Wegovy) with their specific continuation criteria

Differential effects of linagliptin on the function of human islets isolated from non-diabetic and diabetic donors

Dermal hypersensitivity reaction to semaglutide: two case reports

Romero-Gomez M, Lawitz E, Shankar RR, Chaudhri E, Liu J, Lam RL, et al